We are live on ! Find out more
AMAG

AMAG Pharmaceuticals
AMAG

Delisted

AMAG was delisted on the 13th of November, 2020.

Back to rankings

187 hedge funds and large institutions have $774M invested in AMAG Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 68 increasing their positions, 54 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 20

26% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 54

7% more funds holding

Funds holding: 174 → 187 (+13)

3% less capital invested

Capital invested by funds: $802M → $774M (-$28M)

76% less call options, than puts

Call options by funds: $3.87M | Put options by funds: $16.4M

Holders
187
Holders Change
+13
Holders Change %
+7.47%
% of All Funds
4.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
35
Increased
68
Reduced
54
Closed
20
Calls
$3.87M
Puts
$16.4M
Net Calls
-$12.5M
Net Calls Change
-$3.13M

Top Buyers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
+$17.7M
2
PP
PDT Partners
New York
+$5.47M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$4.45M
4
TAM
Tocqueville Asset Management
New York
+$4M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.99M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$25.5M
2
Citadel Advisors
Citadel Advisors
Florida
-$21.7M
3
GAM
Gotham Asset Management
New York
-$6.87M
4
State Street
State Street
Massachusetts
-$6.1M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$6.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$6.86M +$162K +8,709 +2%
NI
27
Numeric Investors
Massachusetts
$6.47M -$4.83M -259,100 -42%
PP
28
PDT Partners
New York
$5.41M +$5.47M +293,400 New
PPA
29
Parametric Portfolio Associates
Washington
$5.25M -$14.9K -798 -0.3%
Principal Financial Group
30
Principal Financial Group
Iowa
$4.93M -$8.14K -437 -0.2%
AQR Capital Management
31
AQR Capital Management
Connecticut
$4.3M -$1.49M -80,105 -26%
PAM
32
Panagora Asset Management
Massachusetts
$4.08M +$805K +43,193 +24%
TAM
33
Tocqueville Asset Management
New York
$3.96M +$4M +214,510 New
T. Rowe Price Associates
34
T. Rowe Price Associates
Maryland
$3.63M -$191K -10,236 -5%
GC
35
Guggenheim Capital
Illinois
$3.46M +$426K +22,834 +14%
Ameriprise
36
Ameriprise
Minnesota
$3.45M +$5.68K +305 +0.2%
CEI
37
Clark Estates Inc
New York
$3.01M +$246K +13,200 +9%
TCIM
38
TIAA CREF Investment Management
New York
$2.9M -$290K -15,585 -9%
Skandinaviska Enskilda Banken (SEB)
39
Skandinaviska Enskilda Banken (SEB)
Sweden
$2.9M -$155K -8,300 -5%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$2.86M -$199K -10,700 -6%
AIM
41
Alambic Investment Management
California
$2.79M +$1.43M +76,842 +103%
Bank of Montreal
42
Bank of Montreal
Ontario, Canada
$2.63M +$498K +26,736 +23%
Squarepoint
43
Squarepoint
New York
$2.51M +$2.54M +136,133 New
Invesco
44
Invesco
Georgia
$2.49M -$25.5M -1,367,753 -91%
GCP
45
GSA Capital Partners
United Kingdom
$2.46M +$751K +40,270 +43%
JCP
46
Jabre Capital Partners
Switzerland
$2.21M +$2.24M +120,000 New
ECM
47
EII Capital Management
New York
$2.21M +$654K +35,090 +41%
VCM
48
Voce Capital Management
California
$2.04M +$311K +16,680 +18%
QI
49
QS Investors
New York
$2.03M +$242K +12,997 +13%
Deutsche Bank
50
Deutsche Bank
Germany
$2.01M -$504K -27,040 -20%
1
2
3 4 5

AMAG Hedge Fund Activity: Q3 2017 in Review

187 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q3 2017, worth a combined $774M — down 3.5% from $802M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new AMAG positions and 20 closed out — a net gain of 15 holders — while 68 added to existing stakes and 54 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $17.7M. The largest seller was Invesco, cutting an estimated $25.5M.

  • 187 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q3 2017, up from 174 in Q2 2017.
  • Funds reported $774M of AMAG Pharmaceuticals stock for Q3 2017, down 3.5% quarter-over-quarter.
  • 35 funds opened new AMAG Pharmaceuticals positions in Q3 2017 and 20 closed out, a net change of +15 holders.
  • The largest AMAG Pharmaceuticals buyer in Q3 2017 was Camber Capital Management, an estimated $17.7M added.
  • The largest AMAG Pharmaceuticals seller in Q3 2017 was Invesco, an estimated $25.5M sold.

Based on aggregated 13F filings for Q3 2017.